corona disease COVID-19 infection
Conditions
Interventions
None listed
Sponsors
Medisch Universitair Ziekenhuis Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: COVID-19 ICU survivors: - Proven COVID-19 infection for which they were admitted to ICU for at least 3 days - Included in the MaastrICCht cohort (a large database of serial measurements collected during ICU stay from patients with COVID-19 admitted to the ICU in het Maastricht University Medical Centre+; METC 2020-1565/3 00 523) - Age >= 18 years - Informed consent - Sufficient command of the Dutch language to follow test instructions and understand the information letter, informed consent, and questionnaires ICU survivors: - Admission to the intensive care unit at the Maastricht UMC+ for at least 3 days - Reason for ICU admission: severe infection (bacterial, viral, fungal) with respiratory insufficiency - If tested for COVID-19 on ICU, negative PCR test result; if not tested for COVID-19 on ICU, no suspicion for COVID-19 positive infection - Age >= 18 years - Informed consent - Sufficient command of the Dutch language to follow test instructions and understand the information letter, informed consent, and questionnaires
Exclusion criteria
Exclusion criteria: COVID-19 ICU survivors: - Objective cognitive impairments before the hospital admission for the COVID-19 infection - An unexpected incident leading to severe neurological damage after hospital discharge (such as stroke or traumatic brain injury) - Contra-indications for MRI scanning (e.g. metal implants, cardiac pacemaker, claustrophobia, pregnancy and tattoos in the head/neck region) - Unwillingness to be informed about clinical relevant (abnormal) MRI-findings - Physical inability to travel to one of the locations (e.g., bedridden patients) ICU survivors: - Positive COVID-19 PCR test during ICU admission - Objective cognitive impairments before the ICU admission - An unexpected incident leading to severe neurological damage after hospital discharge (such as stroke or traumatic brain injury) - Contra-indications for MRI scanning (e.g. metal implants, cardiac pacemaker, claustrophobia, pregnancy and tattoos in the head/neck region) - Unwillingness to be informed about clinical relevant (abnormal) MRI-findings - Physical inability to travel to one of the locations (e.g., bedridden patients).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Radiological outcome at 12-24 months follow-up: MRI abnormalities, focussing on vascular abnormalities and olfactory tractus (3T MRI), and glymphatics and the brainstem (7T MRI). Neurological outcome: residual neurological symptoms (including smell/taste) and functional status at follow-up. Clinical outcome: severity of disease scores, (serial) factors of hypercoagulability and inflammation during ICU admission, neurological and cardiovascular (arterial/venous) complications during hospital admission. | — |
Secondary
| Measure | Time frame |
|---|---|
| Neuropsychological outcome: global deficits in cognitive and neurological functioning, objective changes in or loss of smell/taste and residual signs of inflammation and hypercoagulopathy at follow-up. | — |
Countries
Netherlands
Outcome results
None listed